Developing and optimizing a personalized probiotic treatment regime for nasal endogenous *Staphylococcus aureus* decolonization

Burcu Tepekule[1#], Judith Bergadà-Pijuan[2], Thomas Scheier[2],
Huldrych F. Günthard[2], Markus Hilty[3*], Roger D. Kouyos[2,4*], Silvio D. Brugger[2*]

[1]Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.

[2]Department of Infectious Diseases and Hospital Epidemiology,
University Hospital Zurich, University of Zurich, Switzerland.

[3]Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

[4]Institute of Medical Virology, University of Zurich, Switzerland.

[#]Corresponding authors: `bt6725@princeton.edu, roger.kouyos@usz.ch`

[*]These authors contributed equally.

1 Abstract

Despite the increasing burden of antibiotic resistance, current approaches to eradicate pathobionts such as *Staphylococcus aureus* from the nasal cavity are based on the use of antibacterial agents. An alternative approach is the artificial inoculation of commensal bacteria, i.e., probiotic treatment, which is supported by the increasing evidence for commensal-mediated inhibition of pathogens. To systematically investigate the potential and the limitations of this approach, we developed a quantitative framework simulating the dynamics of the nasal bacterial microbiome by combining mathematical microbiome modeling with longitudinal metagenomic data. By inferring the structure and the magnitude of microbial interaction parameters using metagenomic data, and then simulating the nasal microbial dynamics of patients colonized with *S. aureus* , we could compare the decolonization performance of probiotic and antibiotic treatments under different assumptions on patients' bacterial community composition and susceptibility profile. To further compare the robustness of these treatments, we simulated a *S. aureus* challenge following each treatment and quantified the recolonization probability. Our results suggest that probiotic treatment clearly outperforms antibiotics in terms of decolonization performance, recolonization robustness, and leads to less collateral reduction of the microbiome diversity. Moreover, we find that recolonization robustness is highest in those patients that were not

initially colonized by *Dolosigranulum pigrum*. Thus, probiotic treatment may provide a promising alternative to combat antibiotic resistance, with the additional advantage of personalized treatment options via using the patient's own metagenomic data to tailor the intervention. The *in silico* framework developed in this work is an important step forward to further investigate this alternative in clinical trials.

2 Introduction

The global emergence and spread of antimicrobial resistance (AMR) is of great concern to public health, and threatens the achievements of modern medicine such as organ transplantation, immunomodulation, and implantation of foreign material. Despite the increasing problem of AMR, there are no validated treatments for many resistant infections apart from the prevention strategies such as hospital infection control procedures and antimicrobial stewardship programs [1]. Therefore, new solutions to control the colonization and thus the infection of drug resistant pathogens are urgently needed both to reduce antibiotic consumption and to treat resistant or recurrent infections. One emerging alternative is the microbiota-mediated therapeutics used for the decolonization of such resistant bacteria [2,3].

In terms of AMR, one of the major threats is the spread of the resistant Gram-positive bacteria, such as methicillin-resistant *Staphylococcus aureus* (MRSA) and multidrug resistant (MDR) *Streptococcus pneumoniae*, which are associated with poor clinical outcomes [4, 5]. The first step to invasive disease caused by the pathobionts *S. aureus* and *S. pneumoniae* is colonization [6]. Nasal carriage of these bacteria is a well documented risk factor for skin and soft tissue infections, pneumonia, surgical-site-infections, and bacteremia, and cause significant morbidity and mortality worldwide [7–14]. Despite the increasing problem of AMR, current methods to eradicate these pathobionts from the nasal cavity are based on the use of antibacterial agents, such as the application of mupirocin for *S. aureus* [15–17]. It has been repeatedly shown that mupirocin treatment can promote the emergence of antibiotic resistance in *S. aureus* [18], including MRSA [19]. As a result, non-antibiotic microbiota-targeted therapy seems to be a promising alternative approach based on the increasing data on commensal-mediated inhibition of pathogens.

There has been accumulating evidence on *Corynebacterium* and *Dolosigranulum* species providing colonization resistance against *S. aureus* and *S. pneumoniae* in the nasal cavity of humans. Multiple studies reported a higher relative abundance of *Corynebacterium* species in people who are

not colonized with *S. aureus* [20–23]. It has been repeatedly observed that *Corynebacterium* and *Dolosigranulum* spp. abundances are negatively associated with *S. pneumoniae* colonization in infants [24, 25]. Airway microbiota dominated by *Corynebacterium* plus *Dolosigranulum* genera are associated with favorable clinical outcomes compared to microbiota dominated by more pathogenic bacteria such as *Staphylococcus* and *Streptococcus* [26]. Similarly, *Corynebacterium* and *Dolosigranulum* were negatively associated with *S. pneumoniae* carriers compared to non-carriers [27]. It has been demonstrated that the absolute abundance of *Dolosigranulum* species is a predictor of *S. aureus* carriage in a threshold-dependent manner [28]. Additionally, it has been shown that *D. pigrum* alone inhibited *S. aureus*, but *D. pigrum* plus *C. pseudodiphtheriticum*, together, inhibited *S. pneumoniae* *in vitro* [29].

Despite the mounting evidence mentioned above, mechanisms by which these common commensal organisms eliminate *S. aureus* or *S. pneumoniae* colonization are not exactly clear [30]. A commonly proposed hypothesis suggests that secondary metabolites appear to govern bacterial competition in the human nose and may become important agents for eradication of opportunistic pathogens from human microbiota [30, 31]. *D. pigrum* may employ multiple mechanisms to inhibit *S. aureus* growth, including bacteriocins or other bioactive small molecules [29]. Similarly, Corynebacteria are also known for the ability to synthesize bacteriocin-like antimicrobial substances [32]. It has been shown that *Corynebacterium* species excrete a to-be-identified substance that inhibits the pathogenic activity of *S. aureus* [33]. Hence, clinical use of these commensal organisms appear to be an alternative option to antibiotic treatment. In fact, it has been shown that decolonization of *S. aureus* by the artificial inoculation of commensal bacteria is possible in clinical setups. As an example, *Corynebacterium pseudodiphtheriticum* was inoculated in six MRSA colonized men and led to a decrease in abundance of *S. aureus* [34]. Similarly, when *Corynebacterium* strain Co304 was inoculated in the nasal cavities of over a dozen adults, *S. aureus* was eradicated in 71% of the subjects and maintained in follow up periods of up to 3 years [35]. These studies confirm once more that the knowledge on the inhibitory capabilities of certain commensals can be translated into clinical practice. Given the complex interaction between the multiple species composing the microbiota and the resulting multitude of indirect consequences of interventions targeting the microbiota, mathematical modeling of the commensal-mediated inhibition of pathogens may help and inform the translation of such strategies by exploring the range of possible outcomes and their determinants in a systematic and controlled manner, enabling personalized microbiota-targeted therapies.

Previous research has produced considerable amount of data on the composition of microbial communities in the upper respiratory tract, and successfully identified certain qualitative relationships between the key residents of the nasal microbiota [20–29]. However, all this information on the community composition and the pairwise interactions still remain mostly on a descriptive level, focusing on the correlations of presence and absence of the microbial species. A complementary approach is to incorporate this data in a dynamical model, where the interactions between microbial species could be inferred and followed temporally. Such a multi-compartmental, dynamical model would allow for complex interactions and feedback loops to result in outcomes that could not have been directly predicted by observing pairwise microbial interactions in isolation. Consequently, it would provide a mechanistical understanding of the temporal dynamics of the nasal biota, which has the potential to be manipulated for positive health outcomes as suggested by descriptive clinical studies. With this motivation, we develop a quantitative framework to design and simulate a treatment regime by the artificial inoculation of beneficial commensals *D. pigrum* and *C. pseudodiphtheriticum*, based on the evidence that their presence in the nasal cavity is negatively correlated with *S. aureus* and *S. pneumoniae* colonization. By bringing the qualitative information and the data together in an integrative framework, we provide a quantitative representation of the microbiome dynamics in the nose. Dynamical modeling of the nasal microbiome allows us to make quantitative predictions regarding the effect of clinical interventions, such as different decolonization procedures and antibiotic treatment regimens. Moreover, our framework has the potential to be extended as a personalized-treatment tool for precision probiotics, which can be used by physicians in a clinical setting.

3 Results

Development of our computational framework can be summarized in three steps: data curation, model building and parametrization, and the implementation of the treatment regimens followed by a *S. aureus* challenge (Fig. 1) (see Methods). Our mathematical model describes the temporal nasal microbial dynamics of a patient already colonized with *S. aureus* , and our simulations include a 5-day long pretreatment regimen with mupirocin in accordance with current eradication protocols, followed by either antibiotic or probiotic treatment, and finally a *S. aureus* challenge by the reintroduction of *S. aureus* to the nasal cavity. Our quantitative analysis is based on the comparison of the antibiotic and probiotic treatments by their decolonization performance and their robustness against *S. aureus* recolonization.

After the growth and interaction parameters were filtered according to the criteria for *S. aureus* and *S. pneumoniae* co-existence and the relative magnitude of certain inter-oligotypes interaction terms (see Methods), we were left with 954 and 929 parameter sets out of 1000 initially sampled for Population 1 (in which patients are already colonized with *S. aureus* but assumed to harbor no *D. pigrum* prior to treatment) and 2 (in which patients are already co-colonized both with *D. pigrum* and *S. aureus* prior to treatment), respectively. Each of these sets represented a distinct patient, and the simulations were repeated for each set for all the combinations of variables, which are the number of treatment courses, inoculum of the probiotic cocktail, switching rates between persistent and susceptible phenotypes, and the timing and inoculum of the *S. aureus* challenge. In our model, persister cells represent a subpopulation of cells that can survive antibiotic treatment via going into a dormant state without being resistant [36], i.e., by being temporarily "not susceptible". An example of the dynamics of the mathematical model is presented in Fig. 2, where the same system is simulated with and without persisters for antibiotic and probiotic treatments. These simulations suggest that persisters may represent an obstacle for achieving *S. aureus* decolonization by antibiotic treatment, whereas the probiotic treatment is more robust to persisters. We therefore start by systematically considering the more conservative assumption of systems without *S. aureus* persisters and then assess the impact of different persister frequencies.

Probiotic treatment has a higher probability of *S. aureus* decolonization. In case of no persisters, over all the inoculum sizes and number of treatment courses, probiotic treatment significantly outperforms antibiotic treatment in terms of *S. aureus* decolonization except for a few cases



Figure 1: Illustration summarizing the development of the computational framework, which can be summarized in three steps: data curation [29, 37], model building and parametrization, and the implementation of the treatment regimens followed by the *S. aureus* challenge. As an outlook, our computational framework can be extended as a personalized-treatment tool for precision probiotics, and can be used by physicians in a clinical setting.

where the normalized inoculum size of the probiotic treatment is very low (10^{-1}) and the number of treatment courses are very high (≥ 5) (Fig. 3**a**)). Even in those cases, probiotic treatment leads to a probability of decolonization above 0.9, and the difference in decolonization probability between the antibiotic and the probiotic treatment remains below 0.09. Moreover, a single course of probiotic treatment leads to a decolonization probability between 0.41 to 0.99 depending on the inoculum size, whereas a single course of antibiotic treatment never leads to decolonization.

Antibiotic treatment leads to a faster *S. aureus* regrowth when decolonization fails. To quantify how fast *S. aureus* grows back in case of an unsuccessful decolonization procedure, we checked the time it takes for *S. aureus* to reach 75% of its initial abundance prior to any treatment within the next 36 months following the treatment regimen, which we refer to as *S. aureus* recurrence. Median values of difference in time to recurrence for the probiotic and the antibiotic treatment are given in Fig 3**b**). For the probiotic treatment, recurrence within the next 3 years following treatment only occurs for the combination of minimum normalized inoculum size (10^{-1}) and the minimum number of treatment courses (1), and takes a median value of 21.9 months (standard deviation, sd= 8.5 months).

We found that allowing for *S. aureus* persisters substantially increases the benefits of probiotic treatment compared to antibiotics (Fig. 4). When all combinations of switching rates (including no persisters with a switching rate of 0) are considered, time to recurrence after probiotic treatment takes a median value of 29.5 months (sd = 8.3 months) (Fig. 4**a)**), assuming that persister *S. aureus* cells are equally affected as the susceptible *S. aureus* cells by the inoculum of *D. pigrum* and *C. pseudodiphtheriticum* (see Methods). On the contrary, recurrence within the next 3 years following antibiotic treatment is observed up to 4 treatment courses (20 days of treatment) for all switching rates including 0 (case of no persisters), and for higher switching rates, recurrence can occur up to 7 treatment courses (35 days of treatment) (Fig. 4**b)**).

Antibiotic treatment significantly reduces nasal microbiome diversity at the cost of *S. aureus* decolonization. Antibiotic and probiotic treatment leads to equal probabilities of decolonization when the number of treatment courses are high enough (≥ 5) in case of no persisters (Figs. 3**a)** and **b)**). However, longer durations of antibiotic treatment affects the other members of the nasal microbiome as well, reducing the number of oligotypes present prior to the treatment. In the case of no persisters and within the region where both antibiotic and probiotic treatment leads to equally successful decolonization, the difference between the number of oligotypes still present in the nasal microbiome following treatment has a median value of 14 (Fig. 4**c)**), with probiotic treatment having 16 and antibiotic treatment having 2 oligotypes left on average. Note that this calculation also includes *S. aureus* and *S. pneumoniae* as oligotypes, thus leading to a negative value of -2 when the number of treatment courses is equal to 1 and where probiotic treatment still leads to a successful decolonization of *S. aureus* and *S. pneumoniae* for higher inoculum sizes, whereas antibiotic treatment fails to do so.

Probiotic treatment is significantly more robust to subsequent challenge with *S. aureus* , regardless of *S. pneumoniae* extinction. An example of the dynamics of the *S. aureus* challenge is presented in Fig. 5. Figs. 5**a)** and **c)** represent a patient where the challenge does not lead to *S. aureus* regrowth following the probiotic treatment (hence leads to extinction), but leads to *S. aureus* recolonization following the antibiotic treatment. Figs. 5 **b)** and **d)** represent a patient where the challenge leads to *S. aureus* recolonization following both the antibiotic and the probiotic treatments. The probability of *S. aureus* extinction following the *S. aureus* challenge is used as a metric to asses the robustness of each treatment. For population 1 with no persisters, probiotic treatment had an average extinction probability of 46.1% and was significantly more robust to *S. aureus* challenge than antibiotic treatment which had an average extinction probability of 0.2% (Fig. 6**a)**), where the ex-

tinction probabilities are averaged across the number of treatment courses, normalized inoculum size of the probiotic cocktail, and the normalized inoculum size and the time of the *S. aureus* challenge. On the contrary, for population 2 with no persisters, probiotic treatment had an average extinction probability of 2.2% and the antibiotic treatment had an average extinction probability of 1.3% (Fig. 6**c)**). We segregated the robustness of each treatment by *S. pneumoniae* extinction for each population, since *S. pneumoniae* is the one of the major competitors of *S. aureus* and also targeted by both the antibiotic and probiotic treatments. For the antibiotic treatment, given that *S. pneumoniae* goes extinct during treatment, probability of *S. aureus* extinction in case of a *S. aureus* challenge decreases significantly for both populations (Figs. 6**a)** and **b)** for population 1, Figs. 6**c)** and **d)** for population 2). For population 1, robustness of the probiotic treatment is affected by *S. pneumoniae* extinction less than antibiotic treatment does (Figs. 6**a)** and **b)**), and is almost indifferent to *S. pneumoniae* extinction for population 2 (Figs. 6**c)** and **d)**).



Figure 2: An example of the dynamics of the mathematical model, where the same system is simulated **a), c), e)** with and **b), d), f)** without persisters for only pretreatment, pretreatment followed by antibiotic treatment, and pretreatment followed by probiotic treatment, respectively. _s and _p suffixes in the figure legend represent the susceptible and persistent counterparts of the same oligotype, respectively. See Table 1 for the IDs used for each oligotype. Gray area below the normalized abundance of 10^{-6} represents the region below the extinction threshold.

4 Discussion

Despite the urgent need for new antimicrobial agents, the development of new drugs is declining while resistance to antibiotics is on the rise. The threat of antibiotic resistance is especially important for upper respiratory tract pathogens such as *S. pneumoniae* and *S. aureus* . Although there has been accumulating evidence on the use of commensal bacteria for pathobiont decolonization - both *in vivo*, *in vitro*, and in clinical setups [29,34,35] - to this date it is still not a commonly practiced alternative to antibiotic use. To investigate the potential of this alternative approach based on commensal-mediated inhibition of pathogens in a systematic way, we developed a quantitative framework describing the



Figure 3: Decolonization probability, time to recurrence, and final microbial diversity results for Population 1, with no persisters. **a)** Probability of *S. aureus* decolonization for different number of treatment courses and normalized inoculum sizes. **b)** Median time difference for recurrence between probiotic and antibiotic treatments. **c)** Median microbial diversity difference between probiotic and antibiotic treatments, calculated as the difference of the number of oligotypes still present in the microbiome following treatment. See Supplementary Fig. 1 for the same analysis for Population 2.

dynamics of the nasal microbiome by merging mathematical modeling and the data provided in the literature.

Our results suggest that, on average, probiotic treatment has a higher chance of sustainable *S. aureus* decolonization when compared to antibiotic treatment, even for *D. pigrum* and *C. pseudodiphtheriticum* inoculum sizes lower than commonly practiced in a clinical setup [34,38] (Fig. 3**a)**). When persister *S. aureus* cells are included in the model, antibiotic therapy leads to an even lower chance of decolonization, and shorter time to *S. aureus* recolonization when the decolonization is unsuccessful (Fig. 4**b)**), while probiotic therapy is robustly effective. The choice of adding persister cells to our model stems from the frequently observed phenotypic heterogeneity among the patient-derived *S. aureus* strains [39]. Since the mechanisms of how *D. pigrum* and *C. pseudodiphtheriticum* inhibit the growth of *S. aureus* are not exactly clear [40], we assumed that persister *S. aureus* cells are equally affected as the susceptible *S. aureus* cells by the inoculum of *D. pigrum* and *C. pseudodiphtheriticum* [41]. As a result, introduction of persistence to the model only lowers the average growth rate of *S. aureus* for the probiotic treatment, thus not having a significant effect on its decolonization performance. Although this assumption favors probiotic treatment in terms of decolonization performance, it would not affect its robustness against *S. aureus* challenge, since for most of the parameter



Figure 4: Time to *S. aureus* recurrence for Population 1, with different levels of persisters for the antibiotic, and different normalized inoculum sizes for the probiotic treatments. Gray bars represent durations with a mean value longer than 36 months, meaning that no recurrence is observed within the 3 years following treatment. Error bars display +/− the standard error on the mean recurrence time. See Supplementary Fig. 2 for the same analysis for Population 2.

sets, the new microbial community composition after probiotic treatment does not allow for *S. aureus* to have a positive growth rate (Fig. 6**a)** and **b)**).

Comparing the antibiotic and the probiotic treatment purely by their decolonization performance masks the collateral damage induced by antibiotics when both treatments perform equally well. In fact, when the number of treatment courses is high enough, i.e., the treatment is continued for a sufficient amount of time, both treatments lead to decolonization almost with certainty (Fig 3**a)**). However, such an aggressive application of antibiotics drives other beneficial members of the nasal microbiome to extinction, thus reducing the overall microbial diversity in the nasal cavity (Fig. 3**c)**). Loss in microbial diversity makes the host more susceptible to the effects of environmental exposures, and leads to an increased risk of colonization by pathogenic species, including recolonization by *S. aureus* itself [42]. On the contrary, loss of microbial diversity is significantly lower for probiotic treat-



Figure 5: An example of the dynamics of *S. aureus* challenge for Population 1, where **a) and c)** and **b) and d)** belong to two different patients. *S. aureus* challenge leads to recolonization for both patients following antibiotic therapy (**a)** and **b**)), and for the second patient following probiotic therapy **d)**, whereas *S. aureus* fails to regrow following probiotic treatment for the first patient **c)**. Gray area below the normalized abundance of 10^{-6} represents the region below the extinction threshold.

ment even for high number of treatment courses, allowing the host to still maintain the beneficial bacteria in their nasal cavity, which is essential for upper respiratory tract health.

Due to the impact both treatments have on the microbial community composition, we also investigated how the host would respond to a *S. aureus* challenge after the treatment has ended. Our results suggest that probiotic treatment is more robust to *S. aureus* challenge, i.e., significantly more successful in preventing *S. aureus* recolonization (Fig. 6**a**)), providing the host with recolonization resistance for future *S. aureus* infections. Even for cases where probiotic treatment also decolonized *S. pneumoniae* , which is one of the major competitors of *S. aureus* , robustness of the probiotic treatment was contained (Fig. 6**b**)). On the contrary, antibiotic treatment barely provided any recolonization resistance, supporting the argument for its negative collateral effects on microbial diversity and robustness.

Results above were obtained for Population 1, where *D. pigrum* and *S. aureus* co-existence is not imposed on the model based on the inverse association between *S. aureus* carriage and the presence of *D. pigrum* in the nasal microbiome [20–25, 43]. This means that the model is indifferent to *D. pigrum*



Figure 6: Mean *S. aureus* extinction probabilities for the antibiotic and probiotic treatments followed the *S. aureus* challenge **a)**, **b)** for population 1, and **c)**, **d)** for population 2; **b)**, **d)** where the probabilities are segregated by *S. pneumoniae* extinction.

and *S. aureus* co-existence, and the patients do not harbor *D. pigrum* in their nasal microbiome prior to any treatment. To test the robustness of the probiotic treatment even further, we repeated our *S. aureus* challenge analysis on Population 2, which has the constraint of *S. aureus* and *D. pigrum* co-existence in the nasal microbiome prior to treatment. Although less realistic, it is a more difficult patient population to treat from the probiotic treatment's perspective, since the model parameters allow some amount of the treatment itself, i.e., *D. pigrum* , to already co-exist with the pathogen, i.e., *S. aureus* , prior to the application of probiotics. Unsurprisingly, robustness of the probiotic treatment was significantly lower for Population 2, but was still higher compared to the antibiotic treatment (Fig. 6**c)**). Segregation of the results by *S. pneumoniae* decolonization led to similar results as with Population 1, and revealed that the low levels of colonization resistance provided by the antibiotic treatment can mostly be attributed to *S. pneumoniae* still being a part of the nasal microbiome (Fig. 6**d)**), which is also a risk factor for pneumonia, otitis media, sepsis, etc.

Although having two different patient populations provided valuable insights on treatment robustness, inferring interaction parameters for *D. pigrum* using a sample taken from a patient belonging to Population 1 is theoretically impossible. Since *D. pigrum* is assumed to be absent prior to any treatment, its interaction with other oligotypes including itself in the nasal microbiome can not be estimated, imposing an epistemic limitation on parameter inference. We circumvented this limitation via sampling from posterior distributions obtained by using samples where *D. pigrum* is present in the nasal cavity prior to treatment, implicitly assuming that interaction parameters involving *D. pigrum* would be similar when *D. pigrum* and *S. aureus* can co-colonize the nasal cavity to a certain extend.

We used 16S rRNA gene sequencing results based on samples taken from infants, whereas our probiotic treatment regimen is targeted for adults, which is another limitation of our study. However, this was the most detailed longitudinal dataset we had access to, allowing us to build a more detailed model regarding temporal microbial community dynamics.

Despite the indisputable advantages of probiotic treatment suggested by our results, our analysis is conservative in terms of favoring probiotic treatment. Our model imposes an equal inoculum and identical timing on *D. pigrum* and *C. pseudodiphtheriticum* application, which can easily be modified and has the potential to improve the decolonization outcomes for shorter treatment durations. Furthermore, such modifications can be based on the metagenomic data of the patient and can even be personalized. Our analysis including two patient populations depending on their *D. pigrum* colonization prior to treatment already provides important insights on how sensitive the nasal microbiome might be to recolonization by an environmental *S. aureus* exposure, thus informing the clinicians to take further prevention measures depending on the specific patient.

Although some concerns regarding the safety of probiotics targeting gut microbiome were raised by several clinical trials [44], studies based on the nasal application of probiotics only revealed minor side effects [38], and considered to be safe [29, 45–47]. On the contrary, application of antibiotics is quite detrimental to the overall microbial diversity [48], contributing to the emergence and spread of antibiotic resistance and thus jeopardizing the success of the future treatments that would be necessary [49].

Given the public-health crisis associated especially with MRSA, it is obvious that we have to accelerate the process of developing alternative treatments. This is only possible if modeling goes hand in hand

with clinical practice, establishing an iterative flow of information. The quantitative framework on commensal-mediated inhibition of pathogens provided in this study is a crucial step forward for the translation of experimental and clinical data into mainstream clinical practice in a systematic and controlled manner. Our approach could be used both for guiding strategies to treat disease, and to inform clinical trial design to optimize human microbiota composition to prevent pathogen colonization and thus to prevent bacterial disease. All these clinically important outcomes would also lower the economic burden of antibiotic treatment and healthcare costs, and provide the option of a personalized treatment instead of a "one-fits-all" approach.

5 Methods

Our computational framework simulates the nasal microbial community dynamics of a patient who is already colonized with *S. aureus* , and goes through either probiotic or antibiotic treatment for decolonization. As the conventional clinical practice, a 5-day long pretreatment regimen with mupirocin is prescribed prior to both treatments. After the pretreatment, the patient either continues to use mupirocin (antibiotic treatment), or applies a probiotic cocktail of *D. pigrum* and *C. pseudodiphtheriticum* to the nasal cavity on a daily basis for *S. aureus* decolonization (probiotic treatment). The patient is challenged with a certain inoculum of *S. aureus* after the treatment is complete to further asses the robustness of the respective treatment to recolonization. Considering the role of antibiotic-persistent bacteria in severe invasive infections which are often difficult to treat, all simulations are repeated with different levels of antibiotic-persistent *S. aureus* to understand the role of persistence in pathogen decolonization. Development of our framework is summarized in Fig. 1.

5.1 Data Curation

To build and parameterize our dynamical model, we used the 16S rRNA gene sequencing data obtained from the nasal swabs of healthy infants (provided in [37]). This data contained relative abundances of nasal microbial oligotypes belonging to 47 infants in total, which had to be filtered and aligned in time before it could be used for parametrization. First, data belonging to first 12 weeks of life is discarded to avoid any bias that can be introduced by the maternal nasal microbiome. Afterwards, we have identified the infants with a nasal microbiome composition such that *S. aureus* and *S. pneumoniae* constitutes at least 25% on average of the overall *Staphylococcaceae* and *Streptococcaceae* abundance within the time frame the samples were taken to represent the nasal biota of the already colonized individuals. This abundance threshold is determined heuristically to avoid numerical issues in the

inference procedure related to extinction events. After the selection of the infants was complete (11 subjects were left out of 47), their samples are aligned in time according to the month they were taken to represent the seasonal aspects of the microbial abundance distribution. Key table for the oligotypes included during model building is given in Table 1, as described in Mika *et al.* [37,50]. Assuming that the biomass of the samples were constant, relative abundance values are considered to represent the normalized abundance values, normalized by the total biomass of the nasal cavity.

Simultaneously, we have integrated the following qualitative data sources to obtain a priori information on the directionality and the magnitude of the interactions between our focal nasal microbial oligotypes:

1. ***C. pseudodiphtheriticum* promotes the growth of *D. pigrum* (positive interaction term).** Based on the experimental results reported by Brugger *et al.*, *D. pigrum* benefits from the presence of *C. pseudodiphtheriticum* in terms of growth, but *C. pseudodiphtheriticum* is mainly unaffected by the presence of *D. pigrum in vitro* [29]. This suggests a relatively mono-directional interaction between these two commensal species.

2. ***S. pneumoniae* and *S. aureus* inhibit the growth of each other (negative interaction term).** The negative association between *S. aureus* and *S. pneumoniae* is well documented [51, 52], and hypothesized to be due to H_2O_2 [53, 54] and/or the pilus produced by *S. pneumoniae* [55] *in vitro*. On the other hand, data from animal models show that this negative association cannot be explained by H_2O_2-mediated killing of cooccuring bacteria [56]. Consequently, despite the evidence for this negative association, the underlying mechanism remains unclear [40]. Therefore, this inhibition is represented in the interaction terms rather than any other additional mechanism.

3. ***D. pigrum* inhibits the growth of *S. pneumoniae* and *S. aureus* (negative interaction term), *C. pseudodiphtheriticum* inhibits the growth of *S. pneumoniae* and *S. aureus* (negative interaction term), and *D. pigrum* inhibits the growth of *S. aureus* more than it inhibits the growth of *S. pneumoniae* .** There has been accumulating evidence on *Corynebacterium* and *Dolosigranulum* species providing colonization resistance against *S. aureus* and *S. pneumoniae* in the nasal cavity of humans. Multiple studies reported a higher relative abundance of *Corynebacterium* species in people who are not colonized with *S. aureus* [20–23]. It has also been repeatedly demonstrated that *Corynebacterium* and *Dolosigranulum* spp. abundances are negatively associated with *S. pneumoniae* colonization in infants [24,25,43]. Airway microbiota dominated by *Corynebacterium* plus *Dolosigranulum* genera are associated

Family	**ID**	**Corresponding Oligotype**
Pasteurellaceae	P1	CA (*H. influenzae*/aegyptius)
Pasteurellaceae	P2	TCC (H. aeqyptius)
Pasteurellaceae	P3	CCC (H. influenzae/aegyptius)
Pasteurellaceae	P4	CCT (H. influenzae)
Pasteurellaceae	P5	TA (H. aeqyptius)
Pasteurellaceae	P6	TCTTA (H. influenzae)
Corynebacteriaceae	C1	G (C. pseudodiphtheriticum/propinquum)
Corynebacteriaceae	C2	T- (C. accolens)
Staphylococcaceae	Sta1	TC (S. aureus)
Staphylococcaceae	Sta2	AA (S. capitis/ S. caprae/B. amyloliquefaciens)
Staphylococcaceae	Sta3	TT (S. aureus)
Staphylococcaceae	Sta4	AGA (S. pasteuri/warneri)
Moraxellaceae	M1	CA (M. nonliquefaciens/catarrhalis)
Moraxellaceae	M2	TA (M. lincolnii)
Moraxellaceae	M3	CG (M. nonliquefaciens/catarrhalis)
Moraxellaceae	M4	TGT (M. lincolnii)
Moraxellaceae	M5	AC (M. osloensis)
Streptococcaceae	Stre1	G (S. pseudopneumoniae/pneumoniae)
Streptococcaceae	Stre2	CT (S. dentisani/oralis/mitis/tigurinus/oligofermentans/infantis)
Carnobacteriaceae	Carnobacteriaceae	D. pigrum*

Table 1: Key Table for Oligotypes belonging to the longitudinal 16S rRNA gene sequencing data. *Since oligotyping was not performed for *D. pigrum* , total Carnobacteriaceae abundance is assumed to represent *D. pigrum* abundance, as it is the only member of the family.

with favorable clinical outcomes compared to microbiota dominated by more pathogenic bacteria such as *Staphylococcus* and *Streptococcus* [26]. Similarly, *Corynebacterium* and *Dolosigranulum* were negatively associated with *S. pneumoniae* carriers compared to non-carriers [27]. It has been shown that the absolute abundance of *Dolosigranulum* species is a predictor of *S. aureus* carriage in a threshold-dependent manner [28], and *D. pigrum* alone inhibits *S. aureus*, but *D. pigrum* plus *C. pseudodiphtheriticum*, together, inhibits *S. pneumoniae in vitro* [29].

5.2 Model building and Parametrization

The dynamical model. We used a generalized Lotka-Volterra (gLV) model with a total of 40 compartments representing the normalized abundance of the oligotypes in Table 1, including their susceptible and persister counterparts. Our model is given by the Eq. Set 1, and the model parameters and variables with their corresponding descriptions are provided in Table 2. Total microbial load in the nasal cavity is assumed to be 10^6 colony-forming units (CFU), meaning that the extinction threshold for normalized abundances is set to 10^{-6}.

$$\begin{aligned} \frac{dx_s^j}{dt} &= \alpha^j x_s^j + \sum_{i=1}^{K} \beta_{ij} x_s^j (x_s^i + x_p^i) - \lambda_{s2p}^j x_s^j + \lambda_{p2s}^j x_p^j - \mathbb{1}\delta^j x_s^j, \\ \frac{dx_p^j}{dt} &= \epsilon\alpha^j x_p^j + \sum_{i=1}^{K} \beta_{ij} x_p^j (x_s^i + x_p^i) + \lambda_{s2p}^j x_s^j - \lambda_{p2s}^j x_p^j. \end{aligned} \tag{1}$$

Growth and interaction parameters. To estimate the growth rates and interaction parameters using the longitudinal 16S rRNA gene sequencing data, we adapted the MDSINE package provided in [57], which is a Markov Chain Monte Carlo (MCMC) based algorithm. Although this estimation algorithm restricts growth rates to have positive and intra-oligotypes interaction terms to have negative values, there are no constraints on other interactions terms. To impose our assumptions provided in the previous section, we manipulated the algorithm so that certain interaction terms are also restricted in their directionality. Instead of using the mean values of the posterior distributions of the growth and interaction terms, we sampled these parameters from the posterior distributions to represent the variability in the parameter space. By doing so, we produced a population of models with different quantitative values for each parameter, but with identical constraints. This is analogous to a patient population with the same eligibility criteria for a clinical trial, i.e., a set of simulations using the same dynamical model but different interaction matrices and growth rates sampled from the same posterior distributions.

Parameter	**Description**	**Remarks**
K	Number of oligotypes.	Number of compartments is double the number of oligotypes, since each oligotype has a susceptible and a persistent counterpart.
x_s^j	Oligotype j, sensitive.	Although the general equations are built such that each susceptible oligotype has a persister counterpart, only *S. aureus* is assumed to switch between the two phenotypes.
x_p^j	Oligotype j, persistent.	
α^j	Growth rate of susceptible oligotype j.	
ϵ	Relative growth rate of persister oligotype j.	
β_{ij}	Pair-wise interaction term between oligotype i and j .	Effect of the normalized abundance of oligotype i on the normalized abundance of oligotype j.
λ_{s2p}^j	Switching rate from susceptible to persister cells.	
λ_{p2s}^j	Switching rate from persister to susceptible cells.	
δ^j	Killing rate of mupirocin for susceptible cells.	Persister cells are assumed to be fully persistent to the application of mupirocin.
$\mathbb{1}$	Binary indicator of mupirocin treatment.	

Table 2: Descriptions of the parameters and variables used in the mathematical model given by Eqn. Set 1.

Treatment parameters. Killing rate of mupirocin is adjusted such that on average 99% of all the oligotypes except the ones in the family *Corynebacteriaceae* (C1 and C2) is cleared during pretreatment [58]. Effect of *D. pigrum* and *C. pseudodiphtheriticum* on *S. aureus* are determined by the inter-oligotypes interaction parameters. The probiotic cocktail consisted of an equal inoculum of *C. pseudodiphtheriticum* and *D. pigrum* , where the normalized inoculum size of each commensal is varied from 10^{-1} to 10^{3}. Each treatment course is assumed to last for 5 days and the number of treatment courses varied between 0 (only pretreatment) to 8 (40 days).

Persistence parameters. Persistence is implemented as a random phenotypic switch between two forms of *S. aureus* , susceptible and persister cells, that are genetically identical. Persisters are the minor subpopulation which are growing slower and showing lower susceptibility to antibiotics relative to the susceptible cells [59]. Growth rate of persister *S. aureus* are assumed to be 1/20 of that of susceptible *S. aureus* ($\epsilon = 0.05$) [59], and are assumed to be fully persistent to the application of mupirocin with a relative death rate of 0. Switching rates between two phenotypes are adopted from [59] and [60]. Since the mechanisms of how *D. pigrum* and *C. pseudodiphtheriticum* inhibit the growth of *S. aureus* are not exactly clear [40], we assume that persister and susceptible *S. aureus* cells have identical inter- and intra-oligotype interaction terms, i.e., their normalized abundances are equally effected by the normalized abundances of other oligotypes.

Challenge parameters. Normalized inoculum size and the timing of the *S. aureus* challenge is set to vary between 10^{-5} to 10^{3} and 1 to 120 days following the completion of the antibiotic or probiotic treatment, respectively.

5.3 Treatment and challenge simulations

Simulations are implemented as follows, and a brief illustration of the simulation scheme is provided in Fig. 7.

1. Growth and interaction parameters are jointly sampled from the posterior distributions estimated using the 16S rRNA gene sequencing data [37] and the modified version of the MDSINE package [57].

2. Among the sampled parameter sets, ones where *D. pigrum* inhibits the growth of *S. aureus* more than it inhibits the growth of *S. pneumoniae* are chosen [1].

[1] Although we modified the MDSINE algorithm for certain interaction parameters to take strictly negative or positive

3. Using these parameter sets, steady state abundances of the dynamical model is obtained for a given set of persistence parameters. Steady states are calculated with the initial conditions reflecting two different patient populations,

   3.1. **Population 1:** Initial conditions reflect the mean normalized abundances of the 16S rDNA data **with the exception of *D. pigrum* abundance being zero**. This condition is based on the inverse association between *S. aureus* carriage and the presence of *D. pigrum* in the nasal microbiome [20–25, 43], and makes the model indifferent to *D. pigrum* and *S. aureus* co-existence.

   3.2. **Population 2:** Initial conditions reflect the mean normalized abundances of the 16S rDNA data **including the mean value for the *D. pigrum* abundance**. This condition imposes *D. pigrum* and *S. aureus* co-existence on the model prior to any treatment.

4. To represent the already colonized patients, parameter sets leading to the coexistence of *S. aureus* and *S. pneumoniae* are chosen. **At this step, each parameter set that is chosen for each population represents one distinct patient.**

5. For each patient,

   5.1. **Pretreatment :** Mupirocin treatment is applied for 5 days. Patients who are still colonized with *S. aureus* after the pretreatment are chosen for further treatment steps.

      5.1.1. **Antibiotic treatment:** Following the pretreatment, mupirocin treatment is continued for a given number of treatment courses, i.e., the abundance of all oligotypes except C1 and C2 is decreased by the killing rate of mupirocin during the simulations.

      5.1.2. **Probiotic treatment:** Following the pretreatment, probiotic cocktail is applied for a given number of treatment courses, i.e., the abundance of *Carnobacteriaceae* and C1 are increased by the normalized inoculum size at the time points of probiotic application during the simulations.

values, the magnitude of these values are free to vary. Therefore, this filtering step had to be implemented after the parameter estimation is complete.

Both simulations are continued until the steady-state is reached and the data regarding the microbial abundances are kept for each time step to be later used as the initial conditions for the challenge simulations depending on the time of *S. aureus* inoculation.

5.2. ***S. aureus* challenge :** After the treatment is complete, patients' nasal cavity is challenged with *S. aureus* , i.e, the normalized abundance of *S. aureus* is increased by the challenge inoculum size at the time point of the challenge during the simulations. Simulations are continued until the new steady-state is reached.



Figure 7: Illustration summarizing the simulation scheme. Color codes represent distinct parameter sets, and the shapes represent the population type, where triangles and squares belong to Population 1 and Population 2, respectively.

6 Financial Support

This work was supported by the Promedica Foundation (Grant 1449M to S.D.B.), the Gebert Rüf Foundation (Microbials Grant GRS−09420 to S.D.B. and M.H.), Swiss National Science Foundation (SNF) (Grant BSSGI0_155851), as well as Forschungskredit (K−84804 − 01 − 01) to B.T.

References

[1] Livia Gargiullo, Federica Del Chierico, Patrizia D'Argenio, and Lorenza Putignani. Gut microbiota modulation for multidrug-resistant organism decolonization: present and future perspectives. *Frontiers in microbiology*, 10:1704, 2019.

[2] Chandradhish Ghosh, Paramita Sarkar, Rahaf Issa, and Jayanta Haldar. Alternatives to conventional antibiotics in the era of antimicrobial resistance. *Trends in microbiology*, 27(4):323–338, 2019.

[3] Rekha B Panwar, Richard P Sequeira, and Thomas B Clarke. Microbiota-mediated protection against antibiotic-resistant pathogens. *Genes & Immunity*, 22(5):255–267, 2021.

[4] Holger Schmid, Andre Romanos, Helmut Schiffl, and Stephan R Lederer. Persistent nasal methicillin-resistant staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome. *BMC nephrology*, 14(1):1–9, 2013.

[5] Françoise Van Bambeke, René R Reinert, Peter C Appelbaum, Paul M Tulkens, and Willy E Peetermans. Multidrug-resistant streptococcus pneumoniae infections. *Drugs*, 67(16):2355–2382, 2007.

[6] Elisa Margolis, Andrew Yates, and Bruce R Levin. The ecology of nasal colonization of streptococcus pneumoniae, haemophilus influenzae and staphylococcus aureus: the role of competition and interactions with host's immune response. *BMC microbiology*, 10(1):59, 2010.

[7] Santiago Ewig, Antoni Torres, Mustafa El-Ebiary, Neus Fàbregas, Carmen Hernandez, Julià Gonzalez, Jose Maria Nicolas, and Luis Soto. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury: incidence, risk factors, and association with ventilator-associated pneumonia. *American journal of respiratory and critical care medicine*, 159(1):188–198, 1999.

[8] Christof Von Eiff, Karsten Becker, Konstanze Machka, Holger Stammer, and Georg Peters. Nasal carriage as a source of staphylococcus aureus bacteremia. *New England Journal of Medicine*, 344(1):11–16, 2001.

[9] Susan S Huang and Richard Platt. Risk of methicillin-resistant staphylococcus aureus infection after previous infection or colonization. *Clinical Infectious Diseases*, 36(3):281–285, 2003.

[10] Heiman FL Wertheim, Margreet C Vos, Alewijn Ott, Alex van Belkum, Andreas Voss, Jan AJW Kluytmans, Peter HJ van Keulen, Christina MJE Vandenbroucke-Grauls, Marlene HM Meester, and Henri A Verbrugh. Risk and outcome of nosocomial staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. *The Lancet*, 364(9435):703–705, 2004.

[11] Kepler A Davis, Justin J Stewart, Helen K Crouch, Christopher E Florez, and Duane R Hospenthal. Methicillin-resistant staphylococcus aureus (mrsa) nares colonization at hospital admission and its effect on subsequent mrsa infection. *Clinical Infectious Diseases*, 39(6):776–782, 2004.

[12] Heiman FL Wertheim, Damian C Melles, Margreet C Vos, Willem van Leeuwen, Alex van Belkum, Henri A Verbrugh, and Jan L Nouwen. The role of nasal carriage in staphylococcus aureus infections. *The Lancet infectious diseases*, 5(12):751–762, 2005.

[13] Rupak Datta and Susan S Huang. Risk of infection and death due to methicillin-resistant staphylococcus aureus in long-term carriers. *Clinical Infectious Diseases*, 47(2):176–181, 2008.

[14] B Quintero, M Araque, C Van Der Gaast-de Jongh, F Escalona, M Correa, S Morillo-Puente, S Vielma, and PWM Hermans. Epidemiology of streptococcus pneumoniae and staphylococcus aureus colonization in healthy venezuelan children. *European journal of clinical microbiology & infectious diseases*, 30(1):7–19, 2011.

[15] Suzanne F Bradley. Mrsa colonisation (eradicating colonisation in people without active/invasive infection). *BMJ clinical evidence*, 2011, 2011.

[16] Kevin W McConeghy, Dennis J Mikolich, and Kerry L LaPlante. Agents for the decolonization of methicillin-resistant staphylococcus aureus. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 29(3):263–280, 2009.

[17] Miranda van Rijen, Marc Bonten, Richard Wenzel, and Jan Kluytmans. Mupirocin ointment for preventing staphylococcus aureus infections in nasal carriers. *Cochrane database of systematic reviews*, (4), 2008.

[18] Erik Bathoorn, David J Hetem, Jeriela Alphenaar, Johannes G Kusters, and Marc JM Bonten. Emergence of high-level mupirocin resistance in coagulase-negative staphylococci associated with increased short-term mupirocin use. *Journal of clinical microbiology*, 50(9):2947–2950, 2012.

[19] Aisling R Caffrey, Brian J Quilliam, and Kerry L LaPlante. Risk factors associated with mupirocin resistance in meticillin-resistant staphylococcus aureus. *Journal of Hospital Infection*, 76(3):206–210, 2010.

[20] AS Alvarez, L Remy, C Allix-Béguec, C Ligier, C Dupont, O Leminor, C Lawrence, P Supply, D Guillemot, JL Gaillard, et al. Patient nostril microbial flora: individual-dependency and diversity precluding prediction of s taphylococcus aureus acquisition. *Clinical microbiology and infection*, 20(1):70–78, 2014.

[21] Daniel N Frank, Leah M Feazel, Mary T Bessesen, Connie S Price, Edward N Janoff, and Norman R Pace. The human nasal microbiota and staphylococcus aureus carriage. *PloS one*, 5(5):e10598, 2010.

[22] Ryan C Johnson, Michael W Ellis, Jeffrey B Lanier, Carey D Schlett, Tianyuan Cui, and D Scott Merrell. Correlation between nasal microbiome composition and remote purulent skin and soft tissue infections. *Infection and immunity*, 83(2):802–811, 2015.

[23] Miling Yan, Sünje J Pamp, Julia Fukuyama, Peter H Hwang, Do-Yeon Cho, Susan Holmes, and David A Relman. Nasal microenvironments and interspecific interactions influence nasal microbiota complexity and s. aureus carriage. *Cell host & microbe*, 14(6):631–640, 2013.

[24] Melinda M Pettigrew, Alison S Laufer, Janneane F Gent, Yong Kong, Kristopher P Fennie, and Joshua P Metlay. Upper respiratory tract microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children. *Appl. Environ. Microbiol.*, 78(17):6262–6270, 2012.

[25] Alison S Laufer, Joshua P Metlay, Janneane F Gent, Kristopher P Fennie, Yong Kong, and Melinda M Pettigrew. Microbial communities of the upper respiratory tract and otitis media in children. *MBio*, 2(1):e00245–10, 2011.

[26] Yanjiao Zhou, Daniel Jackson, Leonard B Bacharier, David Mauger, Homer Boushey, Mario Castro, Juliana Durack, Yvonne Huang, Robert F Lemanske, Gregory A Storch, et al. The upper-airway microbiota and loss of asthma control among asthmatic children. *Nature Communications*, 10(1):1–10, 2019.

[27] Wouter AA de Steenhuijsen Piters, Simon P Jochems, Elena Mitsi, Jamie Rylance, Sherin Pojar, Elissavet Nikolaou, Esther L German, Mark Holloway, Beatriz F Carniel, Mei Ling JN Chu, et al.

Interaction between the nasal microbiota and s. pneumoniae in the context of live-attenuated influenza vaccine. *Nature communications*, 10(1):1–9, 2019.

[28] Cindy M Liu, Lance B Price, Bruce A Hungate, Alison G Abraham, Lisbeth A Larsen, Kaare Christensen, Marc Stegger, Robert Skov, and Paal Skytt Andersen. Staphylococcus aureus and the ecology of the nasal microbiome. *Science advances*, 1(5):e1400216, 2015.

[29] Silvio D Brugger, Sara M Eslami, Melinda M Pettigrew, Isabel F Escapa, Matthew T Henke, Yong Kong, and Katherine P Lemon. Dolosigranulum pigrum cooperation and competition in human nasal microbiota. *Msphere*, 5(5), 2020.

[30] Bernhard Krismer, Christopher Weidenmaier, Alexander Zipperer, and Andreas Peschel. The commensal lifestyle of staphylococcus aureus and its interactions with the nasal microbiota. *Nature reviews microbiology*, 15(11):675, 2017.

[31] Daniela Janek, Alexander Zipperer, Andreas Kulik, Bernhard Krismer, and Andreas Peschel. High frequency and diversity of antimicrobial activities produced by nasal staphylococcus strains against bacterial competitors. *PLoS pathogens*, 12(8):e1005812, 2016.

[32] A Kwaszewska and EM Szewczyk. Production of antibacterial substances by resident corynebacteria isolated from human skin. *Medycyna Doświadczalna*, 59(3):256, 2007.

[33] Matthew M Ramsey, Marcelo O Freire, Rebecca A Gabrilska, Kendra P Rumbaugh, and Katherine P Lemon. Staphylococcus aureus shifts toward commensalism in response to corynebacterium species. *Frontiers in microbiology*, 7:1230, 2016.

[34] Y Uehara, H Nakama, K Agematsu, M Uchida, Y Kawakami, ASM Abdul Fattah, and N Maruchi. Bacterial interference among nasal inhabitants: eradication of staphylococcus aureus from nasal cavities by artificial implantation of corynebacterium sp. *Journal of Hospital Infection*, 44(2):127–133, 2000.

[35] NV Kiryukhina, VG Melnikov, AV Suvorov, Yu A Morozova, and VK Ilyin. Use of corynebacterium pseudodiphtheriticum for elimination of staphylococcus aureus from the nasal cavity in volunteers exposed to abnormal microclimate and altered gaseous environment. *Probiotics and antimicrobial proteins*, 5(4):233–238, 2013.

[36] Nathalie Q Balaban, Sophie Helaine, Kim Lewis, Martin Ackermann, Bree Aldridge, Dan I Andersson, Mark P Brynildsen, Dirk Bumann, Andrew Camilli, James J Collins, et al. Definitions

and guidelines for research on antibiotic persistence. *Nature Reviews Microbiology*, 17(7):441–448, 2019.

[37] Moana Mika, Ines Mack, Insa Korten, Weihong Qi, Suzanne Aebi, Urs Frey, Philipp Latzin, and Markus Hilty. Dynamics of the nasal microbiota in infancy: a prospective cohort study. *Journal of allergy and clinical immunology*, 135(4):905–912, 2015.

[38] Ilke De Boeck, Marianne FL van den Broek, Camille N Allonsius, Irina Spacova, Stijn Wittouck, Katleen Martens, Sander Wuyts, Eline Cauwenberghs, Katarina Jokicevic, Dieter Vandenheuvel, et al. Lactobacilli have a niche in the human nose. *Cell reports*, 31(8):107674, 2020.

[39] Julian Bär, Mathilde Boumasmoud, Srikanth Mairpady Shambat, Clément Vulin, Markus Huemer, Tiziano A Schweizer, Alejandro Gómez-Mejia, Nadia Eberhard, Yvonne Achermann, Patrick O Zingg, et al. Quantification of within-patient staphylococcus aureus phenotypic heterogeneity as a proxy for the presence of persisters across clinical presentations. *Clinical Microbiology and Infection*, 2022.

[40] Christopher Weidenmaier, Christiane Goerke, and Christiane Wolz. Staphylococcus aureus determinants for nasal colonization. *Trends in microbiology*, 20(5):243–250, 2012.

[41] Simon Heilbronner, Bernhard Krismer, Heike Brötz-Oesterhelt, and Andreas Peschel. The microbiome-shaping roles of bacteriocins. *Nature Reviews Microbiology*, 19(11):726–739, 2021.

[42] Ni Zhao, Dina F Khamash, Hyunwook Koh, Annie Voskertchian, Emily Egbert, Emmanuel F Mongodin, James R White, Lauren Hittle, Elizabeth Colantuoni, and Aaron M Milstone. Low diversity in nasal microbiome associated with staphylococcus aureus colonization and bloodstream infections in hospitalized neonates. In *Open forum infectious diseases*, volume 8, page ofab475. Oxford University Press US, 2021.

[43] Emma K Accorsi, Eric A Franzosa, Tiffany Hsu, Regina Joice Cordy, Ayala Maayan-Metzger, Hanaa Jaber, Aylana Reiss-Mandel, Madeleine Kline, Casey DuLong, Marc Lipsitch, et al. Determinants of staphylococcus aureus carriage in the developing infant nasal microbiome. *Genome biology*, 21(1):1–24, 2020.

[44] Gui Yang, Zhi-Qiang Liu, and Ping-Chang Yang. Treatment of allergic rhinitis with probiotics: an alternative approach. *North American journal of medical sciences*, 5(8):465, 2013.

[45] Stephany Flores Ramos, Silvio D Brugger, Isabel Fernandez Escapa, Chelsey A Skeete, Sean L Cotton, Sara M Eslami, Wei Gao, Lindsey Bomar, Tommy H Tran, Dakota S Jones, et al. Genomic stability and genetic defense systems in dolosigranulum pigrum, a candidate beneficial bacterium from the human microbiome. *Msystems*, 6(5):e00425–21, 2021.

[46] Ilke De Boeck, Stijn Wittouck, Katleen Martens, Irina Spacova, Eline Cauwenberghs, Camille Nina Allonsius, Jennifer Jörissen, Sander Wuyts, Wannes Van Beeck, Jelle Dillen, et al. The nasal mutualist dolosigranulum pigrum ambr11 supports homeostasis via multiple mechanisms. *Iscience*, 24(9):102978, 2021.

[47] Rachael Lappan and Christopher S Peacock. Corynebacterium and dolosigranulum: future probiotic candidates for upper respiratory tract infections. *Microbiology Australia*, 40(4):172–177, 2019.

[48] Manuel Ferrer, Celia Méndez-García, David Rojo, Coral Barbas, and Andrés Moya. Antibiotic use and microbiome function. *Biochemical pharmacology*, 134:114–126, 2017.

[49] Burcu Tepekule, Pia Abel zur Wiesch, Roger D Kouyos, and Sebastian Bonhoeffer. Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota. *Proceedings of the National Academy of Sciences*, 116(46):23106–23116, 2019.

[50] Moana Mika, Josua Maurer, Insa Korten, Aurélie Allemann, Suzanne Aebi, Silvio D Brugger, Weihong Qi, Urs Frey, Philipp Latzin, and Markus Hilty. Influence of the pneumococcal conjugate vaccines on the temporal variation of pneumococcal carriage and the nasal microbiota in healthy infants: a longitudinal analysis of a case–control study. *Microbiome*, 5(1):1–14, 2017.

[51] Gili Regev-Yochay, Ron Dagan, Meir Raz, Yehuda Carmeli, Bracha Shainberg, Estela Derazne, Galia Rahav, and Ethan Rubinstein. Association between carriage of streptococcus pneumoniae and staphylococcus aureus in children. *Jama*, 292(6):716–720, 2004.

[52] Debby Bogaert, Alex van Belkum, Marcel Sluijter, Ad Luijendijk, Ronald de Groot, HC Rümke, HA Verbrugh, and PWM Hermans. Colonisation by streptococcus pneumoniae and staphylococcus aureus in healthy children. *The Lancet*, 363(9424):1871–1872, 2004.

[53] Gili Regev-Yochay, Krzysztof Trzciński, Claudette M Thompson, Richard Malley, and Marc Lipsitch. Interference between streptococcus pneumoniae and staphylococcus aureus: in vitro hydrogen peroxide-mediated killing by streptococcus pneumoniae. *Journal of bacteriology*, 188(13):4996–5001, 2006.

[54] Bonggoo Park, Victor Nizet, and George Y Liu. Role of staphylococcus aureus catalase in niche competition against streptococcus pneumoniae. *Journal of bacteriology*, 190(7):2275–2278, 2008.

[55] Gili Regev-Yochay, Marc Lipsitch, Alan Basset, Ethan Rubinstein, Ron Dagan, Meir Raz, and Richard Malley. The pneumococcal pilus predicts the absence of staphylococcus aureus co-colonization in pneumococcal carriers. *Clinical Infectious Diseases*, 48(6):760–763, 2009.

[56] Lindsey Bomar, Silvio D Brugger, Brian H Yost, Sean S Davies, and Katherine P Lemon. Corynebacterium accolens releases antipneumococcal free fatty acids from human nostril and skin surface triacylglycerols. *MBio*, 7(1):e01725–15, 2016.

[57] Vanni Bucci, Belinda Tzen, Ning Li, Matt Simmons, Takeshi Tanoue, Elijah Bogart, Luxue Deng, Vladimir Yeliseyev, Mary L. Delaney, Qing Liu, Bernat Olle, Richard R. Stein, Kenya Honda, Lynn Bry, and Georg K. Gerber. Mdsine: Microbial dynamical systems inference engine for microbiome time-series analyses. *Genome Biology*, 17(1):121, Jun 2016.

[58] Tara F Carr, Jennifer L Hill, Alex Chiu, and Eugene H Chang. Alteration in bacterial culture after treatment with topical mupirocin for recalcitrant chronic rhinosinusitis. *JAMA Otolaryngology–Head & Neck Surgery*, 142(2):138–142, 2016.

[59] Tsuyoshi Mikkaichi, Michael R Yeaman, Alexander Hoffmann, and MRSA Systems Immunobiology Group. Identifying determinants of persistent mrsa bacteremia using mathematical modeling. *PLoS computational biology*, 15(7):e1007087, 2019.

[60] Pintu Patra and Stefan Klumpp. Population dynamics of bacterial persistence. *PLoS One*, 8(5):e62814, 2013.